Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin + Ipamorelin Visceral Fat Complete Guide 2026: Peptide Type Comparison

Before committing to the tesamorelin + ipamorelin blend, understanding how these peptides compare to alternatives clarifies why this specific combination targets visceral fat more effectively than single-agent or generic GH approaches. Tesamorelin GHRH recepto

This comparison does not assign a generated winner or score.

  • Before committing to the tesamorelin + ipamorelin blend, understanding how these peptides compare to alternatives clarifies why this specific combination targets visceral fat more effectively than single-agent or generic GH approaches.
  • Tesamorelin
  • GHRH receptor agonist—stimulates pituitary GH release through natural pathway mimicry
  • 15.2% VAT reduction at 26 weeks (Lancet 2010, HIV lipodystrophy cohort)
  • Neutral—does not elevate cortisol or prolactin
  • 2mg subcutaneous daily
  • Gold standard for VAT-specific reduction; FDA-approved for lipodystrophy; requires daily administration
  • Ipamorelin
  • Ghrelin receptor agonist (GHS-R1a)—amplifies GH secretion without appetite stimulation
  • Limited monotherapy data; typically studied as adjunct to enhance GH pulsatility
  • Neutral—selective for GH without ACTH or prolactin activation
  • 200–300mcg 2–3x daily
  • Ideal synergistic partner for tesamorelin; extends GH elevation windows; no cortisol penalty
  • CJC-1295 (DAC)
  • GHRH analogue with extended half-life (6–8 days vs tesamorelin's 26 minutes)
  • Indirect—sustained GH elevation observed but VAT-specific studies lacking
  • Neutral baseline, but prolonged elevation may blunt natural pulsatility over time
  • 2mg once weekly
  • Convenient dosing but loses physiological GH pulse pattern; may reduce receptor sensitivity with chronic use
  • Synthetic GH (Somatropin)
  • Direct exogenous growth hormone—bypasses endogenous regulation entirely
  • Effective for VAT reduction but requires pharmaceutical doses (2–4 IU daily); high cost and side effect profile
  • Suppresses natural GH/GHRH axis; elevates IGF-1 excessively at therapeutic doses
  • 2–4 IU daily subcutaneous
  • Potent but non-selective; risk of insulin resistance, edema, joint pain; reserved for diagnosed GH deficiency
  • GHRP-6
  • Non-selective ghrelin agonist—stimulates GH but also hunger and cortisol
  • Moderate GH elevation but cortisol co-release limits sustained use
  • Elevates cortisol 15–25% per dose; stimulates appetite significantly
  • 100–200mcg 2–3x daily
  • Outdated for fat loss protocols—cortisol elevation promotes VAT deposition, counteracting GH benefit
  • The tesamorelin + ipamorelin combination delivers the highest visceral fat reduction specificity without the hormonal trade-offs that limit other GH-elevating protocols. CJC1295 Ipamorelin 5MG 5MG represents an alternative pairing worth researching for those seeking extended-release GHRH analogues, though the physiological pulse pattern of tesamorelin remains unmatched for VAT targeting.
More references

Related material